Article Text

Download PDFPDF
Molecular characterisation and cetuximab-based treatment in a patient with refractory small bowel adenocarcinoma
  1. Sara De Dosso1,
  2. Francesca Molinari2,
  3. Vittoria Martin2,
  4. Milo Frattini2,
  5. Piercarlo Saletti1
  1. 1Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
  2. 2Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno, Switzerland
  1. Correspondence to Dr Sara De Dosso, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland; Sara.Dedosso{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Small bowel adenocarcinoma (SBA) is an uncommon, aggressive neoplasm and limited data are available to guide systemic therapeutic decisions. Only two prospective studies have evaluated the role of chemotherapy in advanced disease, whilst most of the data are generated from retrospective analyses of single institutions. By analogy with metastatic colorectal cancer (mCRC), fluoropyrimidine-based regimens are commonly used.

The role of biologicals in this disease is as yet unexplored; nonetheless we read with interest the article by Tsang et al on the use of bevacizumab in advanced SBA.1

Cetuximab is a monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR), approved for the treatment of irinotecan-refractory mCRC. In addition, in mCRC it has been shown to improve efficacy in …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.